ArticleMicrosystems & nanoengineering2020
Using intracellular plasmonics to characterize nanomorphology in human cells.
Article in Microsystems & nanoengineering, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Virtual Overlay Staining With Plasmonic Oligomer Metasurface.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Method for nanoparticles uptake evaluation based on double labeled fluorescent cells scanned in enhanced darkfield microscopy.Biomedical optics express · 2023Article
- Nanomaterials in Animal Husbandry: Research and Prospects.Frontiers in genetics · 2022Review
- Cancer-Nano-Interaction: From Cellular Uptake to Mechanobiological Responses.International journal of molecular sciences · 2021Review
- DMD-based hyperspectral microscopy with flexible multiline parallel scanning.Microsystems & nanoengineering · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Determining the characteristics and localization of nanoparticles inside cells is crucial for nanomedicine design for cancer therapy. Hyperspectral imaging is a fast, straightforward, reliable, and accurate method to study the interactions of nanoparticles and intracellular components. With a hyperspectral image, we could collect spectral information consisting of thousands of pixels in a short time. Using hyperspectral images, in this work, we developed a label-free technique to detect nanoparticles in different regions of the cell. This technique is based on plasmonic shifts taking place during the interaction of nanoparticles with the surrounding medium. The unique optical properties of gold nanoparticles, localized surface plasmon resonance bands, are influenced by their microenvironment. The LSPR properties of nanoparticles, hence, could provide information on regions in which nanoparticles are distributed. To examine the potential of this technique for intracellular detection, we used three different types of gold nanoparticles: nanospheres, nanostars and Swarna Bhasma (SB), an Indian Ayurvedic/Sidha medicine, in A549 (human non-small cell lung cancer) and HepG2 (human hepatocellular carcinoma) cells. All three types of particles exhibited broader and longer bands once they were inside cells; however, their plasmonic shifts could change depending on the size and morphology of particles. This technique, along with dark-field images, revealed the uniform distribution of nanospheres in cells and could provide more accurate information on their intracellular microenvironment compared to the other particles. The region-dependent optical responses of nanoparticles in cells highlight the potential application of this technique for subcellular diagnosis when particles with proper size and morphology are chosen to reflect the microenvironment effects properly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.